目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET SIZE ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET ASSESSMENT
2.3 GROWTH FORECAST MODEL
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 EPIGENETICS MARKET OVERVIEW
4.2 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY
4.3 EPIGENETICS PRODUCT MARKET, BY END USER, 2024
4.4 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Declining sequencing costs and time
5.2.1.2 Growing emphasis on population-scale screening initiatives
5.2.1.3 Technological advancements in epigenetics research
5.2.1.4 Rising demand for epigenetic drugs and epigenetic-based therapeutics
5.2.2 RESTRAINTS
5.2.2.1 Limited applications of epigenomic data in toxicology
5.2.2.2 Data privacy concerns and security issues
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging applications of epigenetics
5.2.3.2 Integration of multi-omics
5.2.4 CHALLENGES
5.2.4.1 Concerns regarding quality of antibodies
5.2.4.2 Challenges associated with epigenetic editing
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 INVESTMENT AND FUNDING SCENARIO
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Single-cell sequencing
5.8.1.2 Chromatin immunoprecipitation
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.2.1 DNA methylation microarrays
5.8.2.2 CRISPR-based genome editing
5.9 PATENT ANALYSIS
5.10 TRADE DATA ANALYSIS
5.10.1 IMPORT DATA
5.10.2 EXPORT DATA
5.11 KEY CONFERENCES AND EVENTS, 2025-2026
5.12 TARIFF AND REGULATORY LANDSCAPE
5.12.1 TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00
5.12.2 REGULATORY FRAMEWORK
5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA
5.15 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
5.15.1 INTRODUCTION
5.15.2 MARKET POTENTIAL OF AI IN EPIGENETICS
5.15.3 AI USE CASES
5.15.4 KEY COMPANIES IMPLEMENTING AI/GEN AI
5.15.5 FUTURE OF AI/GEN AI IN EPIGENETICS MARKET
5.16 IMPACT OF 2025 US TARIFF
5.16.1 INTRODUCTION
5.16.2 KEY TARIFF RATES
5.16.3 PRICE IMPACT ANALYSIS
5.16.4 KEY IMPACTS ON VARIOUS REGIONS
5.16.4.1 US
5.16.4.2 Europe
5.16.4.3 Asia Pacific
5.16.5 END-USE INDUSTRY IMPACT
5.16.5.1 Pharmaceutical and biotech companies
5.16.5.2 Contract Research Organizations (CROs)
5.16.5.3 Academic and research institutes

6 EPIGENETICS MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 KITS & REAGENTS
6.2.1 ANTIBODIES
6.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel market
6.2.2 CHIP-SEQUENCING KITS & REAGENTS
6.2.2.1 Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market
6.2.3 BISULFITE CONVERSION KITS & REAGENTS
6.2.3.1 Effective outcomes associated with bisulfite conversion to sustain growth
6.2.4 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
6.2.4.1 Ability to maintain relative proportions of genes in original pool to stimulate growth
6.2.5 5-HMC & 5-MC ANALYSIS KITS & REAGENTS
6.2.5.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth
6.2.6 HISTONES
6.2.6.1 Emerging importance of chromatin-associated proteins and histones in epigenetic research to bolster growth
6.2.7 OTHER KITS & REAGENTS
6.3 ENZYMES
6.3.1 DNA-MODIFYING ENZYMES
6.3.1.1 Broadening applications of DNA methylation to facilitate growth
6.3.2 PROTEIN-MODIFYING ENZYMES
6.3.2.1 Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to spur growth
6.3.3 OTHER ENZYMES
6.4 INSTRUMENTS & ACCESSORIES
6.4.1 WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO EXPEDITE GROWTH
6.5 SOFTWARE
6.5.1 DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION AND RNA ANALYSIS TO PROMOTE GROWTH
6.6 SERVICES
6.6.1 EXPANDING POOL OF SERVICE PROVIDERS TO DRIVE MARKET

7 EPIGENETICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 NEXT-GENERATION SEQUENCING (NGS)
7.2.1 INCREASING LAUNCHES OF NEXT-GENERATION SEQUENCING PLATFORMS TO FACILITATE GROWTH
7.3 PCR & QPCR
7.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET
7.4 MASS SPECTROMETRY
7.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET
7.5 SONICATION
7.5.1 RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO EXPEDITE GROWTH
7.6 OTHER TECHNOLOGIES

8 EPIGENETICS MARKET, BY METHOD
8.1 INTRODUCTION
8.2 DNA METHYLATION
8.2.1 INCREASING RESEARCH & DEVELOPMENT ACTIVITIES TO SPUR GROWTH
8.3 HISTONE MODIFICATIONS
8.3.1 GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
8.4 OTHER METHODS

9 EPIGENETICS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 ONCOLOGY
9.2.1 GROWING INVESTMENT IN EPIGENETIC-BASED RESEARCH TO BOOST MARKET
9.3 METABOLIC DISEASES
9.3.1 EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO FAVOR GROWTH
9.4 IMMUNOLOGY
9.4.1 GROWING DEMAND FOR EPIGENETIC PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE MARKET
9.5 DEVELOPMENTAL BIOLOGY
9.5.1 INCREASING RESEARCH ON CELL GROWTH AND DIFFERENTIATION TO PROPEL MARKET
9.6 CARDIOVASCULAR DISEASES
9.6.1 EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING ETIOLOGY OF CARDIOVASCULAR DISEASES TO AID GROWTH
9.7 OTHER APPLICATIONS

10 EPIGENETICS PRODUCTS MARKET, BY END USER
10.1 INTRODUCTION
10.2 ACADEMIC & RESEARCH INSTITUTES
10.2.1 INCREASING PUBLIC-PRIVATE COLLABORATIONS TO FAVOR GROWTH
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 GROWING NUMBER OF CLINICAL TRIALS FOR EPIGENETIC-BASED DRUGS TO FUEL MARKET
10.4 HOSPITALS & CLINICS
10.4.1 GROWING USE OF PERSONALIZED MEDICINE TO PROPEL MARKET
10.5 CONTRACT RESEARCH ORGANIZATIONS
10.5.1 INCREASING DEMAND FOR SCALABLE, HIGH-THROUGHPUT EPIGENETICS KITS TO PROMOTE GROWTH

11 EPIGENETICS SERVICE MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 RISING DEMAND FOR THERAPEUTIC DISCOVERIES TO BOLSTER GROWTH
11.3 ACADEMIC & RESEARCH INSTITUTES
11.3.1 INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH
11.4 HOSPITALS & CLINICS
11.4.1 INCREASING INTEGRATION OF EPIGENETIC ASSAYS INTO CLINICAL DIAGNOSTICS, PROGNOSTICS, AND PERSONALIZED MEDICINE TO AID GROWTH

12 EPIGENETICS MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Strong network of well-established epigenetic product manufacturers to spur growth
12.2.3 CANADA
12.2.3.1 Favorable government initiatives to contribute to growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Significant investments in next-generation sequencing to bolster growth
12.3.3 UK
12.3.3.1 Rising acceptance of genome-based diagnostic techniques to support growth
12.3.4 FRANCE
12.3.4.1 Growing demand for PCR technologies to drive market
12.3.5 ITALY
12.3.5.1 High incidence of cancer to expedite growth
12.3.6 SPAIN
12.3.6.1 Well-established network of research centers and universities to boost market
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 High demand for personalized medicine to accelerate growth
12.4.3 JAPAN
12.4.3.1 Increasing collaborations between research & academic organizations to favor growth
12.4.4 INDIA
12.4.4.1 Expanding base of biotechnology facilities to drive market
12.4.5 AUSTRALIA
12.4.5.1 Growing hub for epigenetics to propel market
12.4.6 SOUTH KOREA
12.4.6.1 Rising burden of chronic diseases to foster growth
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Increasing number of healthcare providers incorporating epigenetic testing to aid growth
12.5.3 MEXICO
12.5.3.1 Growing adoption of cutting-edge technologies to drive market
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.6.2 GCC COUNTRIES
12.6.2.1 Saudi Arabia
12.6.2.1.1 Growing healthcare expenditure to propel market
12.6.2.2 UAE
12.6.2.2.1 Increasing collaborations between public and private sectors to spur growth
12.6.2.3 Rest of GCC countries
12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 RISING DEMAND FOR TARGETED THERAPIES TO AUGMENT GROWTH
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES
13.3 REVENUE ANALYSIS
13.4 MARKET SHARE ANALYSIS
13.5 COMPANY VALUATION AND FINANCIAL METRICS
13.6 BRAND/PRODUCT COMPARISON
13.6.1 THERMO FISHER SCIENTIFIC INC.
13.6.2 ILLUMINA, INC.
13.6.3 MERCK KGAA
13.6.4 DANAHER
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.7.5.1 Company footprint
13.7.5.2 Region footprint
13.7.5.3 Offering footprint
13.7.5.4 Method footprint
13.7.5.5 Technology footprint
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.8.1 PROGRESSIVE COMPANIES
13.8.2 RESPONSIVE COMPANIES
13.8.3 DYNAMIC COMPANIES
13.8.4 STARTING BLOCKS
13.8.5 COMPETITIVE BENCHMARKING
13.8.5.1 Detailed list of key startups/SMEs
13.8.5.2 Competitive benchmarking of key startups/SMEs
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES
13.9.2 DEALS
13.9.3 EXPANSIONS

14 COMPANY PROFILES
14.1 KEY MARKET PLAYERS
14.1.1 THERMO FISHER SCIENTIFIC INC.
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches
14.1.1.3.2 Deals
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 ILLUMINA, INC.
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Product launches
14.1.2.3.2 Deals
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 MERCK KGAA
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 MnM view
14.1.3.3.1 Key strengths
14.1.3.3.2 Strategic choices
14.1.3.3.3 Weaknesses and competitive threats
14.1.4 PACBIO
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches
14.1.4.3.2 Deals
14.1.4.3.3 Expansions
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 DANAHER
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Deals
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 BIO-RAD LABORATORIES, INC.
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.7 ACTIVE MOTIF
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Deals
14.1.8 NEW ENGLAND BIOLABS
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Product launches
14.1.8.3.2 Deals
14.1.9 QIAGEN
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches
14.1.10 ZYMO RESEARCH CORPORATION
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches
14.1.10.3.2 Expansions
14.1.10.3.3 Other developments
14.1.11 REVVITY
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.11.3 Recent developments
14.1.11.3.1 Deals
14.1.12 HOLOGIC, INC.
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.13 F. HOFFMANN-LA ROCHE LTD
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.14 PROMEGA CORPORATION
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.15 EPIGENTEK GROUP INC.
14.1.15.1 Business overview
14.1.15.2 Products offered
14.2 OTHER PLAYERS
14.2.1 EPICYPHER
14.2.2 FIOS GENOMICS
14.2.3 GENOMESCAN
14.2.4 CREATIVE BIOGENE
14.2.5 BPS BIOSCIENCE, INC.
14.2.6 ABNOVA CORPORATION
14.2.7 CREATIVE DIAGNOSTICS
14.2.8 BIOMODAL
14.2.9 INTEGRATED DNA TECHNOLOGIES, INC.
14.2.10 NOVOGENE CO., LTD.

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS